Empery Asset Management LP Takes $2.86 Billion Position in Tenaya Therapeutics, Inc. $TNYA

Empery Asset Management LP purchased a new position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,863,115 shares of the company’s stock, valued at approximately $2,855,228,000. Tenaya Therapeutics makes up about 3.3% of Empery Asset Management LP’s holdings, making the stock its 9th largest position. Empery Asset Management LP owned approximately 1.72% of Tenaya Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of TNYA. GSA Capital Partners LLP acquired a new stake in Tenaya Therapeutics in the 2nd quarter valued at about $1,973,000. Renaissance Technologies LLC lifted its stake in Tenaya Therapeutics by 100.6% in the 1st quarter. Renaissance Technologies LLC now owns 3,713,761 shares of the company’s stock worth $2,571,000 after purchasing an additional 1,862,894 shares in the last quarter. Mirador Capital Partners LP boosted its holdings in shares of Tenaya Therapeutics by 2.0% during the 2nd quarter. Mirador Capital Partners LP now owns 905,097 shares of the company’s stock worth $669,000 after purchasing an additional 18,180 shares during the last quarter. Castleview Partners LLC acquired a new position in shares of Tenaya Therapeutics during the 1st quarter worth approximately $106,000. Finally, Jefferies Financial Group Inc. acquired a new position in shares of Tenaya Therapeutics during the 3rd quarter worth approximately $99,000. 90.54% of the stock is currently owned by institutional investors and hedge funds.

Tenaya Therapeutics Trading Up 1.0%

Shares of NASDAQ:TNYA opened at $0.70 on Friday. The company has a market capitalization of $156.36 million, a price-to-earnings ratio of -1.32 and a beta of 2.83. Tenaya Therapeutics, Inc. has a 12-month low of $0.53 and a 12-month high of $2.35. The business has a 50-day moving average price of $0.76 and a 200 day moving average price of $0.76.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its earnings results on Wednesday, August 5th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.13). The business had revenue of $1.11 million for the quarter, compared to the consensus estimate of $10.00 million. As a group, equities research analysts predict that Tenaya Therapeutics, Inc. will post -0.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

TNYA has been the subject of several recent research reports. Weiss Ratings raised Tenaya Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Wall Street Zen lowered Tenaya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Tenaya Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $4.00.

Tenaya Therapeutics Profile

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.